antonie van leeuwenhoek

(delft, netherlands 1632-1723):

founding father of modern biotechnology

We are proud our firm is named after one of the founding fathers of modern biotechnology: Antonie van Leeuwenhoek. Antonie van Leeuwenhoek was a Dutch scientist that lived in the 17th century: 'The Dutch Golden Age", a period in Dutch history, roughly spanning the 17th century, in which Dutch trade, science, military, and art were among the most acclaimed in the world. He was a Dutch tradesman and scientist and is commonly known as "the Father of Microbiology", and considered to be the first microbiologist.

He is best known for his work on the improvement of the microscope and for his contributions towards the establishment of microbiology. Using his handcrafted microscopes, he was the first to observe and describe single-celled organisms, which he originally referred to as animalculs,and which are now referred to as micro organisms. He was also the first to record microscopic observations of muscle fibers, bacteria, spermatozoa, and blood flow in capillaries (small blood vessels). Leeuwenhoek did not author any books; his discoveries came to light through correspondence with the Royal Society, which published his letters.


an unbiased and independent view on companies in the global life sciences sector

Van Leeuwenhoeck Institute (VLI) provides institutional investors and other professional investors with independent, un-biased research on the real value of innovative Life Sciences companies. Many institutional and individual investors will not invest in companies lacking independent third-party research coverage, yet few investment banks cover this sector because it requires dedicated expertise.

In spite of the lack of quality knowledge on an industry-wide basis, there is increased demand for life science-specific market research as investors are seeking information about leading companies in the sector in order to make well-informed investment decisions.


Biofrontera (B8F.DE, B8F.L): Research Note

Biofrontera AG (B8F.DE, B8F.L) is a biopharmaceutical company specializing in the development of dermatological drugs. Its lead product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate actinic keratosis (AK) on the face and scalp in conjunction with photodynamic therapy (PDT). Recently, the company achieved a major milestone with the acceptance to file of the approval application for Ameluz® by the FDA in the US. Using our valuation model, the Company’s current total value is EUR 120-165 million, or EUR 5.00-7.00 per share.

Anteo Diagnostics (ASX:ADO): Initiating Coverage

Anteo Diagnostics (ASX: ADO) is an Australia based medical technology company that provides scientists in the Life Sciences, In Vitro Diagnostic (IVD), Medical Device and Energy markets with powerful tools developed with its patented core nanotechnology. In August, Anteo entered into an agreement to acquire Belgian diagnostic company DIAsource ImmunoAssays SA. The acquisition provides Anteo with a truly global distribution platform, manufacturing capabilities and a significantly broadened product range, which calls fora rerating of the stock.

Invion Group (ASX:IVX): Initiating Coverage Report 

Invion Group (ASX:IVX) is an Australian based biotech company focused on the development of treatments for large indications in respiratory disease and autoimmune disease. There are a number of key milestones to focus on in the next several months which include: data from the Phase II oral INV102 in patients undergoing smoking cessation, data from a Phase II trial of INV103 in lupus patients and completion of enrolment of the NIH-funded Phase II trial of INV102 in asthma patients. 

Resverlogix (RVX.TO): Initiating Coverage Report 

Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is the first to test the BET inhibition hypothesis as a new approach for reducing major adverse cardiovascular events (MACE) in high risk diabetes and CKD patients.

Cellmid (ASX:CDY): Research Note

Cellmid Limited (ASX:CDY) is an Australian biotechnology company with a revenue generating consumer health division and a strong pipeline around a novel target,  midkine (MK), with applications in the treatment of cancer and inflammatory diseases. Cellmid has a fast growing consumer health division, which is generating increasing revenues from the Company’s proprietary FGF5 inhibitor hair growth products. . In 2015 the Company’s revenues increased by 63% to AUD 1.82 million and it is expected to generate close to AUD 4 million during the 2016 financial year from sales in Australia and Japan alone.

Phosphagenics (ASX:POH): Research Note

Phosphagenics is an Australia based drug delivery company that is commercializing various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM (Targeted Penetration Matrix).  TPM is based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain. 

Simavita (ASX:SVA): Initiating Coverage Report

Simavita Limited (ASX: SVA; TSX-V: SV) is an Australian based medical device company in digital healthcare that has developed an innovative and unique solution for the management of urinary incontinence, with a focus on the elderly. we expect a fivefold increase in revenues in the next 1-2 years that will propel the company towards profitability, especially if Simavita is able to sign up one of the large aged care groups in the US.  Based on NPV based valuation, we believe that Simavita is clearly undervalued at the current share price of AUD 0.45. Using our valuation model, the Company’s current total value is AUD 150-180 million, or AUD 1.60-2.00 per share. 


OncoSil Medical (ASX:OSL): Research Note 

Oncosil Medical (ASX:OSL) is an Australia based Life Sciences company that provides an innovative technology for safer and more effective radiation therapies for difficult to treat cancers like pancreatic cancer and hepatocellular carcinoma (HCC). Its lead product is OncoSil™ for pancreatic cancer. A second indication is HCC. For both indications the company filed for a CE Mark in the EU. On September 6th it was announced that the Notified Body has scheduled a Fast Track review for OncoSil™, which will take place on October 6th.